148 related articles for article (PubMed ID: 25597184)
1. [Updated treatment of castration-resistant prostate cancer].
Xu S; Zhang ZY
Zhonghua Nan Ke Xue; 2014 Dec; 20(12):1136-40. PubMed ID: 25597184
[TBL] [Abstract][Full Text] [Related]
2. Drug therapies for metastatic castration-resistant prostate cancer.
El-Bahesh E; Finianos A; Alfaraj A; Aragon-Ching JB
Future Oncol; 2015; 11(17):2395-403. PubMed ID: 26274603
[TBL] [Abstract][Full Text] [Related]
3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
[TBL] [Abstract][Full Text] [Related]
4. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
[TBL] [Abstract][Full Text] [Related]
5. Modern treatment of metastatic prostate cancer.
Holm HV; Dahl AA; Klepp OH; Fosså SD
Tidsskr Nor Laegeforen; 2017 Jun; 137(11):803-805. PubMed ID: 28597635
[TBL] [Abstract][Full Text] [Related]
6. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
7. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Petrylak DP
Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
[TBL] [Abstract][Full Text] [Related]
8. Managing advanced prostate cancer: the rapidly changing treatment landscape.
Dreicer R
Am J Manag Care; 2014 Dec; 20(12 Suppl):S282-9. PubMed ID: 25734964
[TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy for CRPC].
Ozono S; Furuse H
Nihon Rinsho; 2014 Dec; 72(12):2170-3. PubMed ID: 25518353
[TBL] [Abstract][Full Text] [Related]
10. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
11. Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer?
Dogan M; Erdem GU; Zengin N
Asian Pac J Cancer Prev; 2015; 16(14):6167-9. PubMed ID: 26320514
[TBL] [Abstract][Full Text] [Related]
12. Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer.
Dellis A; Papatsoris AG
Expert Opin Biol Ther; 2014 Jan; 14(1):7-10. PubMed ID: 24074253
[TBL] [Abstract][Full Text] [Related]
13. Emerging drugs for prostate cancer.
Chung PH; Gayed BA; Thoreson GR; Raj GV
Expert Opin Emerg Drugs; 2013 Dec; 18(4):533-50. PubMed ID: 24274615
[TBL] [Abstract][Full Text] [Related]
14. Current, new and novel therapy for castration-resistant prostate cancer.
Gaya JM; Ahallal Y; Sanchez-Salas R; Barret E; Rozet F; Galiano M; Macek P; Durand M; Cerruti J; Prapotnich D; Ropert S; Bennamoun M; Cathelineau X
Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
[TBL] [Abstract][Full Text] [Related]
15. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
[TBL] [Abstract][Full Text] [Related]
16. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
17. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.
Grenader T; Plotkin Y; Gips M; Cherny N; Gabizon A
Oncol Rep; 2014 Jan; 31(1):428-34. PubMed ID: 24247716
[TBL] [Abstract][Full Text] [Related]
18. Progress in the mechanism and drug development of castration-resistant prostate cancer.
Zuo M; Xu X; Li T; Ge R; Li Z
Future Med Chem; 2016 May; 8(7):765-88. PubMed ID: 27149562
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
Yamamoto A; Kato M; Matsui H; Ishida R; Kimura T; Funahashi Y; Sassa N; Matsukawa Y; Kamihira O; Hattori R; Gotoh M; Tsuzuki T
Int J Clin Oncol; 2018 Jun; 23(3):584-590. PubMed ID: 29397469
[TBL] [Abstract][Full Text] [Related]
20. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
